The Covid-19 Pandemic Has Had An Impact On The Global Refractory Glaucoma Treatment Market.
Glaucoma is becoming more common around the world. Glaucoma is the leading cause of irreversible blindness worldwide, according to the Glaucoma Research Foundation. Despite receiving proper treatment, nearly 10% of glaucoma patients experience vision loss. In 2013, it was estimated that 64.3 million people worldwide had glaucoma. Furthermore, the American Academy of Ophthalmology reports that the current prevalence is high in Africa and Latin America. Trabeculectomy surgery is performed on patients who do not respond to medications. However, even after trabeculectomy surgery, a small number of patients do not experience complete relief from their glaucoma. As a result, novel treatment options must be developed in order to provide relief to such patients. Reducing intraocular pressure is the most important long-term medical need of patients with refractory glaucoma.
The rising prevalence of glaucoma and diabetes is expected to drive growth in the global refractory glaucoma treatment market over the forecast period. According to the BrightFocus Foundation, a non-profit organisation, over 80 million people worldwide had glaucoma in 2020, with that number expected to rise to 111 million by 2040. The World Health Organization (WHO) reports that the number of diabetics has increased from 108 million in 1980 to 422 million in 2014. As a result, the global demand for adequate treatment options has skyrocketed.
The COVID-19 pandemic has had an impact on the global Refractory Glaucoma Treatment Market. The market experienced a significant decline as a result of stringent regulations on physical distancing and many countries implementing lockdown policies. However, governments in several countries have begun to relax lockdown regulations, which may provide critical opportunities for market players to regain lost traction.
Comments
Post a Comment